Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle.
Taylor
R S
RS
Department of Public Health and Epidemiology, University of Birmingham, Birmingham B15 2TT. r.s.taylor@bham.ac.uk
Drummond
M F
MF
Salkeld
G
G
Sullivan
S D
SD
D003219:Confidentiality; D003362:Cost-Benefit Analysis; D017277:Drug Approval / Q000191:economics* / Q000331:legislation & jurisprudence; D016527:Drug Costs; D005060:Europe; D006801:Humans; D007391:International Cooperation; D008004:Licensure; D012051:Reimbursement Mechanisms; D014481:United States